We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
+8.65%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$7.44B
AUM Growth
+$696M
Cap. Flow
+$295M
Cap. Flow %
3.96%
Top 10 Hldgs %
25.63%
Holding
169
New
15
Increased
63
Reduced
24
Closed
17

Top Buys

Rank Stock Value
1
ZYME icon
Zymeworks
ZYME
+$57.2M
2
NCNO icon
nCino
NCNO
+$41.7M
3
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$35.5M
4
ARGX icon
argenx
ARGX
+$33.8M
5
SHLS icon
Shoals Technologies Group
SHLS
+$31.8M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$52M
2
VRSK icon
Verisk Analytics
VRSK
+$37.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$26.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$24.1M
5
OKTA icon
Okta
OKTA
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 35.75%
2 Technology 29.25%
3 Industrials 12.31%
4 Consumer Discretionary 7.52%
5 Communication Services 5.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOW icon
26
Lowe's Companies
LOW
$118B
$96.9M 1.3%
499,400
-20,000
-4% -$3.91M
WCN
27
Waste Connections
WCN
$41.9B
$96M 1.29%
804,000
– –
DHI icon
28
D.R. Horton
DHI
$40.7B
$95.4M 1.28%
1,055,493
-7,400
-0.7% -$695K
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$92.2M 1.24%
9,510,000
+1,851,000
+24% +$17.4M
SPT icon
30
Sprout Social
SPT
$509M
$90.5M 1.22%
1,011,920
+1,000
+0.1% +$69.3K
TREX icon
31
Trex
TREX
$4.56B
$90.1M 1.21%
882,000
– –
RXDX
32
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$88.2M 1.18%
3,714,032
– –
RNG icon
33
RingCentral
RNG
$4.48B
$87.9M 1.18%
302,608
+81,500
+37% +$23.3M
KRTX
34
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$85.3M 1.15%
748,000
-223,077
-23% -$26.1M
APTV icon
35
Aptiv
APTV
$12.3B
$84.5M 1.13%
537,000
– –
ENTG icon
36
Entegris
ENTG
$17.8B
$80.1M 1.08%
651,599
+35,500
+6% +$4.08M
MGA icon
37
Magna International
MGA
$19B
$75.6M 1.02%
815,600
-32,400
-4% -$3.09M
PLRX icon
38
Pliant Therapeutics
PLRX
$65.6M
$72M 0.97%
2,471,892
– –
CLDX icon
39
Celldex Therapeutics
CLDX
$3.02B
$70.5M 0.95%
2,108,908
+46,475
+2% +$1.28M
EPIX
40
DELISTED
ESSA Pharma
EPIX
$68.7M 0.92%
2,405,169
– –
PRAX icon
41
Praxis Precision Medicines
PRAX
$8.58B
$67.7M 0.91%
252,470
+18,265
+8% +$6.54M
YETI icon
42
Yeti Holdings
YETI
$3.76B
$63.4M 0.85%
690,000
– –
COLL icon
43
Collegium Pharmaceutical
COLL
$1.17B
$62.2M 0.84%
2,629,593
+201,617
+8% +$4.66M
CCI icon
44
Crown Castle
CCI
$33.4B
$61.1M 0.82%
313,100
-900
-0.3% -$169K
VITL icon
45
Vital Farms
VITL
$536M
$60M 0.81%
3,008,232
– –
PANW icon
46
Palo Alto Networks
PANW
$265B
$55.4M 0.74%
896,022
+600
+0.1% +$35.5K
TSM icon
47
TSMC
TSM
$2.09T
$54.4M 0.73%
453,100
– –
ANNX icon
48
Annexon
ANNX
$863M
$53.3M 0.72%
2,409,166
+404,550
+20% +$8.96M
SHLS icon
49
Shoals Technologies Group
SHLS
$1.49B
$51.4M 0.69%
1,447,460
+1,054,904
+269% +$31.8M
DDOG icon
50
Datadog
DDOG
$95.6B
$50.5M 0.68%
485,104
+14,201
+3% +$1.28M
1
2
3 4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Eventide Asset Management held 169 positions worth $7.44B, up 10% from $6.75B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Eventide Asset Management deployed $295M of net new capital in Q2 2021, opening 15 new positions and adding to 63 existing holdings. Its largest new stake was nCino: 662,500 shares worth $39.7M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Verisk Analytics, an estimated $37.6M trimmed.

  • Eventide Asset Management's largest Q2 2021 buy was nCino: 662,500 shares worth $39.7M.
  • Eventide Asset Management added most to Zymeworks in Q2 2021, an estimated $57.2M increase.
  • Eventide Asset Management's biggest Q2 2021 reduction was Verisk Analytics, cutting an estimated $37.6M.
  • Eventide Asset Management fully exited Sarepta Therapeutics in Q2 2021, selling an estimated $52M.
  • Eventide Asset Management's ten largest holdings make up 26% of its $7.44B portfolio in Q2 2021.
  • Eventide Asset Management opened 15 new positions and closed 17 in Q2 2021.
  • Eventide Asset Management's portfolio value rose 10% quarter-over-quarter to $7.44B.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.